Loading...

FITC anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1.5_FITC_102110
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
  • GK1.5_FITC_102110
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) FITC (filled histogram) or rat IgG2b, κ FITC isotype control (open histogram).
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
100405 50 µg 30 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100406 500 µg 99 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Djokić V, et al. 2019. Front Immunol. 9:2891. PubMed
  2. Katsumura KR, et al. 2018. Proc Natl Acad Sci U S A. 115:E10109. PubMed
  3. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  4. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  5. Qiu Z, et al. 2022. J Exp Med. 219:. PubMed
  6. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
  7. Hamdi L, et al. 2022. Ann Clin Transl Neurol. 9:1792. PubMed
  8. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  9. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  10. Pan Y, et al. 2023. Adv Sci (Weinh). 10:e2206792. PubMed
  11. Wilson NG, et al. 2023. iScience. 26:105991. PubMed
  12. Zhuang WR, et al. 2023. Nat Commun. 14:1675. PubMed
  13. Mackin S, et al. 2023. Nat Microbiol. 8:569. PubMed
  14. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  15. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  16. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  17. Fiedler T, et al. 2023. J Neuroinflammation. 20:100. PubMed
  18. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  19. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  20. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
  21. Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed
  22. Wang X, et al. 2023. Nat Commun. 14:3440. PubMed
  23. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
  24. Iwanami N, et al. 2023. Nat Commun. 14:3645. PubMed
  25. Solvay M, et al. 2023. J Immunother Cancer. 11:. PubMed
  26. Wang Z, et al. 2023. Sci Adv. 9:eabo4100. PubMed
  27. Zhao J, et al. 2021. Emerg Microbes Infect. 10:913. PubMed
  28. Liu J, et al. 2021. Front Immunol. 12:747730. PubMed
  29. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  30. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  31. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  32. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  33. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  34. Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed
  35. Corral D, et al. 2022. Cell Rep. 39:110715. PubMed
  36. Lu R, et al. 2022. Scand J Immunol. 96:e13177. PubMed
  37. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  38. Balood M, et al. 2022. Nature. 611:405. PubMed
  39. Zhu M, et al. 2022. Front Immunol. 13:1019248. PubMed
  40. Zhang Z, et al. 2022. Integr Cancer Ther. 21:15347354221138534. PubMed
  41. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  42. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  43. Chen C, et al. 2022. J Neuroinflammation. 19:315. PubMed
  44. Qin S, et al. 2023. Acta Pharm Sin B. :. PubMed
  45. Merk VM, et al. 2023. Genes Immun. 24:52. PubMed
  46. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  47. Sun Y, et al. 2023. Cell Mol Life Sci. 80:63. PubMed
  48. Hajjar S, et al. 2022. Cell Death Differ. 29:585. PubMed
  49. Sylvester MA, et al. 2022. Am J Physiol Renal Physiol. 322:F245. PubMed
  50. Zander R, et al. 2022. Immunity. 55:475. PubMed
  51. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  52. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  53. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  54. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  55. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  56. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  57. Yang Z, et al. 2022. J Immunother Cancer. 10:. PubMed
  58. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  59. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  60. He R, et al. 2021. J Immunol. 206:2353. PubMed
  61. Ma J, et al. 2020. Adv Sci (Weinh). 7:2000609. PubMed
  62. Fan L, et al. 2021. Cancers (Basel). 13:. PubMed
  63. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  64. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  65. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
  66. Yang F, et al. 2021. Front Microbiol. 11:512581. PubMed
  67. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  68. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  69. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  70. Jiang W, et al. 2022. Front Immunol. 13:878832. PubMed
  71. Toomer G, et al. 2022. Viruses. 14:. PubMed
  72. Sega E, et al. 2008. Int J Radiat Oncol Biol Phys. 71:559. PubMed
  73. Lua Y, et al. 2012. Mol Immunol. 52:229. PubMed
  74. Zasłona Z, et al. 2014. J Immunol. 193:4245. PubMed
  75. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  76. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
  77. Pobezinskaya EL et al. 2019. Front Immunol. 1.079861111 . PubMed
  78. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  79. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  80. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  81. Bangs DJ, et al. 2022. Cell Rep. 38:110266. PubMed
  82. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  83. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  84. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  85. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  86. Altshuler A, et al. 2021. Cell Stem Cell. 28(7):1248-1261.e8. PubMed
  87. Tang Y, et al. 2020. Front Immunol. 11:585918. PubMed
  88. Qi X, et al. 2019. Nat Commun. 10:2141. PubMed
  89. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  90. Aqel SI, et al. 2021. JCI Insight. 6:e142376. PubMed
  91. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  92. Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed
  93. Wang Y, et al. 2022. Acta Pharm Sin B. 12:262. PubMed
  94. Zhou HF, et al. 2022. Front Pharmacol. 13:778755. PubMed
  95. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  96. Mardomi A, et al. 2021. J Cell Physiol. 236:6328. PubMed
  97. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  98. Guan H, et al. 2012. PLoS One. 7:e35650. PubMed
  99. D Kim, S Lee, H Jun 2016. Immunol Cell Biol. 10.1038/icb.2016.98. PubMed
  100. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  101. Molina-Sanchez P, et al. 2020. Gastroenterology. 2203:159. PubMed
  102. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  103. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  104. Thomas S, et al. 2019. J Immunother Cancer. 7:214. PubMed
  105. Tritama E, et al. 2018. Hum Vaccin Immunother. 14:1524. PubMed
  106. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  107. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  108. Anastasiou M, et al. 2021. JCI Insight. 6:. PubMed
  109. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  110. Jiang S, et al. 2020. Scand J Immunol. e12867:91. PubMed
  111. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  112. White C, et al. 2014. J Immunol. 193:5933. PubMed
  113. Zongyi Y, et al. 2017. PLoS One. 10.1371/journal.pone.0189617. PubMed
  114. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  115. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  116. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  117. Feng H, et al. 2020. J Dermatol. 47:147. PubMed
  118. Ren HZ, et al. 2022. J Clin Transl Hepatol. 10:1138. PubMed
  119. Ma X, et al. 2021. Cell Metabolism. 33(5):1001-1012.e5. PubMed
  120. Pedraza–Zamora CP, et al. 2017. Parasite Immunol. 39:4. PubMed
  121. Raineri D, et al. 2021. Biomedicines. 10:. PubMed
  122. He X, et al. 2021. Small. 17:e2007165. PubMed
  123. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  124. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  125. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  126. Wang Z, et al. 2020. J Clin Invest. 130:3717. PubMed
  127. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  128. Cervera–Carrascon V, et al. 2020. Oncoimmunology. 9:1761229. PubMed
  129. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  130. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  131. Wang Z, et al. 2022. Nat Biomed Eng. 6:791. PubMed
  132. Guo P, et al. 2021. J Immunol. 207:408. PubMed
  133. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  134. Lu X, et al. 2016. Nat Commun. 7: 12719. PubMed
  135. Deng Z, et al. 2020. World J Gastrointest Oncol. 1091:12. PubMed
  136. Dmitrieva‐Posocco O et al. 2019. Immunity. 50(1):166-180 . PubMed
  137. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  138. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  139. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  140. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  141. Zhou H, et al. 2022. Oncoimmunology. 11:2057892. PubMed
  142. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  143. Hum NR, et al. 2022. Front Oncol. 12:928474. PubMed
  144. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  145. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  146. Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed
  147. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  148. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  149. Ahmari N, et al. 2016. Physiol Genomics. 48: 526 - 536. PubMed
  150. Ito C, et al. 2015. PLoS One. 10: e0140808. PubMed
  151. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  152. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  153. Zhu Y, et al. 2021. EMBO J. 40:e105320. PubMed
  154. Wang Y, et al. 2021. Front Microbiol. 12:701566. PubMed
  155. Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed
  156. Yang B, et al. 2022. Bioengineered. 13:2685. PubMed
  157. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  158. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  159. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
  160. Kruta M, et al. 2021. Cell Stem Cell. :. PubMed
  161. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  162. Sun H, et al. 2022. Front Immunol. 13:818017. PubMed
  163. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  164. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  165. Lang V, et al. 2021. Elife. 10:. PubMed
  166. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  167. Huang L, et al. 2021. Breast Cancer Res Treat. Online ahead of print. PubMed
  168. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  169. Han F, et al. 2020. Invest Ophthalmol Vis Sci. 61:24. PubMed
  170. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  171. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  172. Mencl S, et al. 2014. J Neuroimmunol. 274:125. PubMed
  173. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  174. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  175. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  176. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  177. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  178. Ma K, et al. 2022. iScience. 25:104347. PubMed
  179. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  180. Gao X, et al. 2022. Front Immunol. 13:799331. PubMed
  181. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
  182. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  183. Li Y, Kaneda T 2016. Sci Rep. 6: 25077. PubMed
  184. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  185. Wang X, et al. 2020. Nat Commun. 4.505555556. PubMed
  186. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  187. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  188. Ouyang S, et al. 2019. J Immunol. 202:1441. PubMed
  189. Reynolds CJ, et al. 2018. Sci Rep. 8:672. PubMed
  190. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  191. He C, et al. 2022. Nat Commun. 13:5459. PubMed
  192. Takaku S, et al. 2022. Evid Based Complement Alternat Med. 2022:6122955. PubMed
  193. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  194. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  195. Li J, et al. 2020. Development. :. PubMed
  196. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  197. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  198. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  199. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  200. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  201. Zan H, et al. 2017. Nat Commun. 8:14244. PubMed
  202. Nechama M, et al. 2018. Nat Commun. 9:1603. PubMed
  203. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  204. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  205. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  206. Zhang Q, et al. 2022. Commun Biol. 5:544. PubMed
  207. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  208. Soria-Castro R, et al. 2020. Sci Rep. 10:17802. PubMed
  209. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  210. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  211. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  212. Da Mesquita S, et al. 2021. Science Advances. 7(21):. PubMed
  213. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  214. Khosravi N, et al. 2018. Cancer Immunol Res. 0.797222222. PubMed
  215. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  216. Ji L et al. 2019. Immunity. 51(2):272-284 . PubMed
  217. Habtetsion T et al. 2018. Cell metabolism. 28(2):228-242 . PubMed
  218. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  219. Pan L, et al. 2022. Front Immunol. 13:837497. PubMed
  220. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  221. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  222. Zhou H, et al. 2021. Cell Death Discov. 7:332. PubMed
  223. Liu Y, et al. 2020. Cell Death Dis. 11:1062. PubMed
  224. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  225. Golan K et al. 2018. Cell stem cell. 23(4):572-585 . PubMed
  226. Sivapatham S, et al. 2019. Front Immunol. 1.865277778. PubMed
  227. Zhao Y, et al. 2020. Front Immunol. 2.572222222. PubMed
  228. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  229. Zhong C, et al. 2021. J Virol. 95:e0092521. PubMed
  230. Magee JA, et al. 2021. Stem Cell Reports. 16:20. PubMed
  231. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  232. Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed
  233. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  234. Sears SM, et al. 2022. Kidney360. 3:818. PubMed
  235. Bryan Hart, Sunhee Lee 2016. PLoS Negl Trop Dis. 10:e0005229. PubMed
  236. Blaszczak AM, et al. 2020. Immunometabolism. 2:00. PubMed
  237. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  238. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  239. Hidalgo San Jose L, et al. 2020. Cell Rep. 30:69. PubMed
  240. Blaszczak AM, et al. 2019. J Immunol. 202:2451. PubMed
  241. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  242. Nakao R, et al. 2022. NPJ Vaccines. 7:153. PubMed
  243. Wang Y, et al. 2022. Nat Commun. 13:1454. PubMed
  244. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  245. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  246. Li Z, et al. 2022. Evid Based Complement Alternat Med. 2022:7421265. PubMed
  247. Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed
  248. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  249. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  250. Hart B, et al. 2015. PLoS Negl Trop Dis. 9: 0004046. PubMed
  251. Bartley A, et al. 2018. Front Physiol. 9:1593. PubMed
  252. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  253. Hong Y, et al. 2019. J Extracell Vesicles. 8:1670893. PubMed
  254. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  255. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  256. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  257. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  258. Kathania M, et al. 2022. Cell Rep. 40:111345. PubMed
  259. Gawish R, et al. 2022. Elife. 11:. PubMed
  260. Li J, et al. 2022. Nat Commun. 13:1481. PubMed
  261. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  262. Gardenier J, et al. 2017. Nat Commun. 8:14345. PubMed
  263. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  264. Zeng A, et al. 2020. Oncol Rep. . PubMed
  265. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  266. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  267. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  268. Lestari SR, et al. 2020. J Ayurveda Integr Med. 11:414. PubMed
  269. Jiang W, et al. 2021. Cell Rep. 37:110112. PubMed
  270. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  271. Ding X, et al. 2021. Front Immunol. 12:667136. PubMed
  272. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  273. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
RRID
AB_312690 (BioLegend Cat. No. 100405)
AB_312690 (BioLegend Cat. No. 100406)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD4
Specificity Alt (DOES NOT SHOW ON TDS):
CD4
App Abbreviation (DOES NOT SHOW ON TDS):
FC,IHC-F,ICC
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

View All CD4 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD4 GK1.5 FC
Biotin anti-mouse CD4 GK1.5 FC,IHC-F,ICC
FITC anti-mouse CD4 GK1.5 FC,IHC-F,ICC
PE anti-mouse CD4 GK1.5 FC
PE/Cyanine5 anti-mouse CD4 GK1.5 FC
Purified anti-mouse CD4 GK1.5 FC,IHC-F,ICC,IP,Costim,Block,Depletion
PE/Cyanine7 anti-mouse CD4 GK1.5 FC
APC/Cyanine7 anti-mouse CD4 GK1.5 FC
Alexa Fluor® 647 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Alexa Fluor® 488 anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Pacific Blue™ anti-mouse CD4 GK1.5 FC
Alexa Fluor® 700 anti-mouse CD4 GK1.5 FC
PerCP anti-mouse CD4 GK1.5 FC
PerCP/Cyanine5.5 anti-mouse CD4 GK1.5 FC
Brilliant Violet 421™ anti-mouse CD4 GK1.5 FC,ICC,IHC-F
Ultra-LEAF™ Purified anti-mouse CD4 GK1.5 FC,Block,Costim,Depletion,IHC,IP
Alexa Fluor® 594 anti-mouse CD4 GK1.5 IHC-F,FC,ICC,SB
Brilliant Violet 711™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 510™ anti-mouse CD4 GK1.5 FC,IHC-F,ICC
Brilliant Violet 605™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 785™ anti-mouse CD4 GK1.5 FC
PE/Dazzle™ 594 anti-mouse CD4 GK1.5 FC
APC/Fire™ 750 anti-mouse CD4 GK1.5 FC
GoInVivo™ Purified anti-mouse CD4 GK1.5 FC
Brilliant Violet 750™ anti-mouse CD4 GK1.5 FC
Brilliant Violet 650™ anti-mouse CD4 GK1.5 FC
Spark Blue™ 550 anti-mouse CD4 GK1.5 FC
Spark NIR™ 685 anti-mouse CD4 GK1.5 FC
KIRAVIA Blue 520™ anti-mouse CD4 GK1.5 FC
PE/Fire™ 640 anti-mouse CD4 GK1.5 FC
APC/Fire™ 810 anti-mouse CD4 GK1.5 FC
PE/Fire™ 700 anti-mouse CD4 GK1.5 FC
Spark Violet™ 538 anti-mouse CD4 GK1.5 FC
Spark YG™ 593 anti-mouse CD4 GK1.5 FC
Spark Blue™ 574 anti-mouse CD4 Antibody GK1.5 FC
Spark UV™ 387 anti-mouse CD4 GK1.5 FC
Spark Blue™ 515 anti-mouse CD4 GK1.5 FC
Spark PLUS UV395™ anti-mouse CD4 GK1.5 FC
Spark Red™ 718 anti-mouse CD4 (Flexi-Fluor™) GK1.5 FC
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account